[Cardiorenal syndrome: the role of new biochemical markers].


Journal Article

Cardiorenal syndrome is a pathophysiological heart and kidney disorder, in which acute or chronic dysfunction of one organ induces a damage in the other. It's a syndrome more and more often encountered in clinical practice and this implies the need to recognize the syndrome through biochemical markers with a good sensitivity and specificity, since its earliest stages in order to optimize therapy. In addition to widely validated biomarkers, such as BNP, pro BNP, creatinine, GFR and cystatin C, other promising molecules are available, like NGAL (neutrophil gelatinase-associated lipocalin, KIM-1 (kidney injury molecule-1), MCP-1 (monocyte chemotactic peptide), Netrin-1, interleuchin 18 and NAG (N-acetyl-β-glucosa-minidase). The role of these emerging biomarkers is still not completely clarified: hence the need of new clinical trials.

Full Text

Cited Authors

  • Vernuccio, F; Grutta, G; Ferrara, F; Novo, G; Novo, S

Published Date

  • December 2012

Published In

Volume / Issue

  • 103 / 12

Start / End Page

  • 559 - 563

PubMed ID

  • 23258238

Pubmed Central ID

  • 23258238

International Standard Serial Number (ISSN)

  • 0034-1193

Digital Object Identifier (DOI)

  • 10.1701/1206.13356


  • ita

Conference Location

  • Italy